BIOMAT Database Logo BIOMAT Database Logo

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. 2000

D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 80262, USA. daniel.kuritzkes@UCHSC.edu

The effect of baseline drug resistance mutations on response to zidovudine, lamivudine, and ritonavir was evaluated in zidovudine-experienced persons infected with human immunodeficiency virus type 1 (HIV-1). Presence of the K70R mutation was associated with significantly higher plasma HIV-1 RNA levels at baseline. However, presence of resistance mutations did not affect the increase in plasma HIV-1 RNA during a 5-week drug washout, nor was there any effect on first-phase virus decay rates after initiation of therapy or on the probability of having plasma HIV-1 RNA levels <100 copies/mL at week 48. Polymorphisms at protease codons 10, 36, and 71 were associated with significantly faster second-phase decay rates. Suppression of plasma HIV-1 RNA despite presence of zidovudine resistance mutations implies that the presence of these mutations does not preclude a durable response to treatment with a potent 3-drug regimen.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
July 2000, AIDS research and human retroviruses,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076.
March 1998, The Journal of infectious diseases,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
December 2002, Antimicrobial agents and chemotherapy,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230.
September 2016, Open forum infectious diseases,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
November 1994, The New England journal of medicine,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
July 1998, The Journal of infectious diseases,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
April 1999, The Journal of infectious diseases,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
July 1995, The Journal of infectious diseases,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
August 2000, The Journal of infectious diseases,
D R Kuritzkes, and A Sevin, and B Young, and M Bakhtiari, and H Wu, and M St Clair, and E Connick, and A Landay, and J Spritzler, and H Kessler, and M M Lederman
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
December 2002, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!